about
A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune CheckpointsImmune Evasion Strategies of GlioblastomaPredictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysisAdvances in the treatment of newly diagnosed glioblastomaTargeting immune checkpoints in malignant gliomaClinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy.The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis.MiR-138 exerts anti-glioma efficacy by targeting immune checkpointsPrioritization schema for immunotherapy clinical trials in glioblastoma.Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cellsMolecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma.MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis.Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy.Glioblastoma targeted therapy: updated approaches from recent biological insights.Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.Immunomonitoring in glioma immunotherapy: current status and future perspectives.Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade.Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma.Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.Immune Checkpoint Inhibitors in Gliomas.Immunotherapy and radiation in glioblastoma.Correlation of immune phenotype with IDH mutation in diffuse glioma.PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions.Bioinformatic Profiling Identifies a Glucose-Related Risk Signature for the Malignancy of Glioma and the Survival of Patients.Vaccine-based immunotherapeutic approaches to gliomas and beyond.Developing immunotherapeutic strategies to target brain tumors.Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma.Concepts in glioma immunotherapy.The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors.Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities.Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis.Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma.Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors.Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma.Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination TherapyPD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
P2860
Q26738729-D0C8F873-0E16-4A60-AE72-F0F1798B840CQ26765855-4E3E0D2E-A1C9-48DE-B6B0-7B558AC495C5Q26769728-B2E5F95D-9F3B-49DF-A17C-A35F6D94464AQ26773514-657050B3-7F18-403B-81CC-C753D62A03A8Q28072012-63582562-FD1B-44DA-A93D-3F5B18623BCBQ28084351-8A23537E-222F-4B3C-A72C-B7D48D229E57Q31156299-28F3F2D5-4647-4CB4-A595-12DA45167004Q33835174-F99492AF-B923-4F37-AA80-6FA352D7BA09Q36785139-4BCBACE3-0412-4AC6-AB6E-6A589EE3AD77Q37078999-708BCA0C-6075-488F-B85E-398FE03F0FF4Q37362929-18B83A92-E582-4688-A893-051C9D6103EAQ37477267-64B14B7E-5D12-441C-81C6-B3BB75C80D43Q37686230-4F0F3406-62A3-4E24-B77C-428203060DA4Q37741143-5077636B-56A3-498E-AE4F-37A73BBD1AEDQ38597700-E9F46B3A-E22F-4269-B5D3-8560F5C3422FQ38635512-D6AFFB43-A418-4918-B687-21AA0D8A8AA2Q38659771-C6EF55C5-CEBD-4B96-998F-6AFCB14F8536Q38691679-540B8C93-38F0-4B50-9726-8A0E2BAA62FFQ38737954-7728292B-A0B6-4002-BA23-3F34A14CA27DQ38743138-B04EFECE-4997-4581-B114-B8853E499AE5Q38743793-95DA7577-EA77-4941-B623-96BC61C21187Q38752191-B03E3AE9-656B-4032-B0D5-976052F7E308Q38771020-9F6310E2-7B35-4D22-AD47-5ABF201FE3ADQ38787346-308F8FE4-DF5B-4DC9-A3D2-BFB101828D46Q38789127-5ED3CBB0-A9FA-402A-AF78-1A724D85A490Q38789860-F110C60A-69D7-4AF5-AD1C-1F8103C00981Q38851464-7A2DF8A9-D631-4337-9486-B344CE360177Q38907925-4D23E5FE-E15D-44AA-967A-9BEFB9F9057EQ38909071-48E5CBDE-C69F-4970-8A61-B3CB94AFB906Q38930244-7B94AED4-6E2E-4A58-9DBF-2980768FE16AQ39045586-5A517BFC-3E07-4C39-9293-A7F8B921543CQ39432561-C0A1813F-A91F-49D6-B3E2-561B7D14758FQ39449408-9AB6D3C6-1560-4336-93AE-FD010F660A7CQ39632681-88D631C8-10F0-4A56-8105-A2CD972EE385Q40213573-BF5E8B9A-29A8-441B-B5D8-44FE4ECF4B29Q40529135-864CD47D-465D-4DEC-BE8B-8DDB4276AF60Q41485890-D928DE08-6536-49A5-AB84-CFB16DE9FCBBQ41592956-F262F48B-A641-4EFC-8313-09ACFAD2F51BQ41654251-611A9165-AEBC-47E5-A90C-E24D6A0622B5Q41903951-C3A6DEDA-F650-4CF8-94CA-5893DE53F687
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
PD-L1 expression and prognostic impact in glioblastoma.
@ast
PD-L1 expression and prognostic impact in glioblastoma.
@en
type
label
PD-L1 expression and prognostic impact in glioblastoma.
@ast
PD-L1 expression and prognostic impact in glioblastoma.
@en
prefLabel
PD-L1 expression and prognostic impact in glioblastoma.
@ast
PD-L1 expression and prognostic impact in glioblastoma.
@en
P2093
P2860
P50
P356
P1433
P1476
PD-L1 expression and prognostic impact in glioblastoma.
@en
P2093
Amy B Heimberger
Charles A Conrad
Jared K Burks
Jie Qing Chen
Konrad Gabrusiewicz
Krit Ritthipichai
Laszlo Radvanyi
Ling-Yuan Kong
Nasser K Yaghi
P2860
P304
P356
10.1093/NEUONC/NOV172
P577
2015-08-30T00:00:00Z